

EVALUATION OF THE EFFECT OF SPECIMEN HANDLING CONDITIONS IN BD VACUTAINER® PPT ON THE STABILITY OF HIV-1 VIRAL LOAD USING ROCHE COBAS® AMPLIPREP/COBAS® TAQMAN® HIV-1 TEST

¹H Fernandes, ¹M Ramanathan, ²S Morosyuk, ³T Do, ²L Rainen

¹University of Medicine and Dentistry of New Jersey, Newark, NJ; ²BD Diagnostics, Franklin Lakes, NJ; ³Roche Molecular Systems, Pleasanton, CA



Introduction

Accurate quantification of HIV-1 RNA is essential to the management of HIV-1 infected patients. The aim of this study was to validate the performance of the BD Vacutainer® Plasma Preparation Tube (PPT™) with the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test and evaluate the effect of the following parameters on HIV-1 viral load:

- 1) Storage of whole blood in PPT for six hours prior to centrifugation.
- 2) Storage of plasma *in situ* in the PPT at room temperature (RT) or 4°C for up to 5 days.
- 3) Agitation (to simulate transport) of the tube followed by a re-centrifugation.

Materials and Methods

Patient Population: Blood was collected from 55 adult, consented HIV+ subjects with previous viral load (VL) test results of <1000 copies/mL.

Collection Tubes:

- Tube A: BD Vacutainer® K₂EDTA Tube, Ref.# 367861
- Tubes B-G: BD Vacutainer® Plasma Preparation Tube (PPT™), Ref. #362788

Assay: Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test (CAP/CTM)

Statistical Analysis:


- Cochran's Q test to compare the proportion of subjects with undetectable viral load count (ND) and results under the limit of detection (LOD) of <48 copies/mL between tubes.
- McNemar's Test for paired samples.
- Analysis of concordance of dichotomized CAP/CTM HIV-1 Test, v1.0 results (<50 copies/mL, ≥50 copies/mL) using 2x2 tables for comparison between results from all PPT tube handling conditions to EDTA results.

Table 1: Available Results per Tube Type and Handling Condition

Tube/Condition	Total Count	*ND Count	Data not available	<48 Copies/mL	>48 Copies/mL
EDTA (A)	55	13	1	11	30
PPT 2H (B)	55	14	1	9	31
PPT 6H (C)	55	18	0	9	28
PPT 1D RT (D)	55	18	0	5	32
PPT 5D 4°C (E)	55	14	0	13	28
PPT invert (F)	55	4	1	6	44
PPT invert/spin (G)	55	15	2	6	32

*ND= Not Detected

Figure 2: Correlation plot of Log₁₀ HIV-1 viral load in PPT 2H (B) to EDTA



Results

Figure 3: Correlation plot of Log₁₀ HIV-1 viral load in PPT 6H (C) to EDTA




Figure 4: Correlation plot of Log₁₀ HIV-1 viral load in PPT 1D RT (D) to EDTA




Figure 5: Correlation plot of Log₁₀ HIV-1 viral load in PPT 5D 4°C (E) to EDTA




Figure 6: Correlation plot of Log₁₀ HIV-1 viral load in PPT invert (F) to EDTA




Figure 7: Correlation plot of Log₁₀ HIV-1 viral load in PPT invert/spin (G) to EDTA





Table 2: Summary of Results per PPT Tube Handling Condition vs. EDTA

Eval. Tube	Number of Subjects With Matched Pair of Results	Both Eval. and EDTA <50cp/mL (Concordant)	Eval. <50cp/mL EDTA ≥50cp/mL (Discordant)	Eval. ≥50cp/mL EDTA <50cp/mL (Discordant)	Both Eval. and EDTA ≥50cp/mL (Concordant)	Overall Agreement ¹ vs. EDTA	P-value for McNemar's Test ²
PPT 2H (B)	53	22	1	1	29	96.2%	1.0000
PPT 6H (C)	54	23	4	1	26	90.7%	0.1797
PPT 1D RT (D)	54	20	3	4	27	87.0%	0.7055
PPT 5D 4°C (E)	54	24	4	0	26	92.6%	0.0455
PPT invert (F)	53	10	0	14	29	73.6%	0.0002
PPT invert/spin (G)	52	19	2	4	27	88.5%	0.4142

¹Per cent overall agreement = Number of subjects with concordant results/Total number of subjects x 100. ²P-value is for McNemar's Test for paired samples with two binary outcomes (<50 copies/mL; ≥50copies/mL). A P-value of <0.05 may indicate a statistically significant difference between the evaluation and control tubes being compared. No adjustment for multiple comparisons was performed.

Figure 1: Study Design



Summary of Results

1. Table 1 shows that the number of specimens with quantifiable HIV-1 VL in Tubes A, B, C, D, E and G was comparable (28 - 32). The tube that was inverted to simulate transportation had more specimens (44) with quantifiable VL.
2. Figures 2-6 show that R² values in correlation plots of evaluation tubes A, B, C, D, and G for comparisons to EDTA control (Tube A) ranged from 91.7% to 93.7% while R² values for comparisons of Tubes E and F to Tube A were 87.2% and 88.6% respectively.
3. Table 2 shows that the PPT invert (Tube F) was significantly different to the EDTA control (Tube A). The PPT 5D at 4°C (Tube E) may also differ from the EDTA control. The p-value for McNemar's Test was < 0.05 for both comparisons, though no adjustment for multiple comparisons was made. The overall agreement, however, for Tube E was 92.6% while that for Tube F was 73.6% indicating that inverting the tube without re-centrifugation may have a greater impact on VL results <50 copies/mL as compared to EDTA than storing the plasma for 5D at 4°C.

Summary

This study shows that with the Roche TaqMan HIV-1 viral load assay (CAP/CTM), HIV VL overall agreement with EDTA is unaffected by:

- Storage of whole blood in PPT for 6h at room temperature before centrifugation
- Storage of plasma overnight *in situ* in PPT at room temperature
- Storage in PPT at 4°C for up to 5 days.

Additionally:

- As compared to EDTA plasma, VLs are increased in a significant number of samples in PPT near or below the LOQ when PPT was inverted and not re-centrifuged.

Conclusions

We conclude that the BD Vacutainer® PPT™ is equivalent to EDTA plasma for HIV-1 viral load as measured by the Roche TaqMan HIV-1 viral load assay (CAP/CTM) if:

- Whole blood is stored in PPT for no longer than 6h at ambient temperature.
- Plasma is stored in PPT for no longer than 1 day at ambient temperature or 5 days at 4°C.
- PPT is re-centrifuged at 600 x g for 5 minutes in the receiving laboratory prior to aliquoting, testing, or further storage.

Acknowledgements

We would like to thank Karen Byron and Valentin Parvu (BD) and John Duncan (Roche Molecular Systems) for statistical analyses.